November 30, 2018 09:53 AM EST
Financing

Prep­ping for key ASH pre­sen­ta­tion, lit­tle Aprea Ther­a­peu­tics gets $57M to fu­el PhI­II p53 can­cer study

John Carroll

Editor & Founder

Sev­en months ago, Stock­holm-based Aprea Ther­a­peu­tics man­aged to re­main al­most com­plete­ly over­looked at AACR when the biotech un­veiled da­ta from a hand­ful of 8 pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times